Qiagen NV's Total Assets for the quarter that ended in Mar. 2026 was €5,001 Mil.
During the past 12 months, Qiagen NV's average Total Assets Growth Rate was 12.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 2.10% per year.
During the past 5 years, the average Total Assets Growth Rate was -0.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 3.10% per year.
During the past 13 years, Qiagen NV's highest 3-Year average Total Assets Growth Rate was 70.70%. The lowest was -3.70%. And the median was 8.10%.
Total Assets is connected with ROA %. Qiagen NV's annualizedROA % for the quarter that ended in Mar. 2026 was 4.54%. Total Assets is also linked to Revenue through Asset Turnover. Qiagen NV's Asset Turnover for the quarter that ended in Mar. 2026 was 0.08.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Qiagen NV's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Qiagen NV Total Assets Related Terms
Qiagen NV Total Assets Historical Data
* Premium members only.
The historical data trend for Qiagen NV's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Qiagen NV's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (XTER:QIA) has a Total Assets of €5,001 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Qiagen NV and its competitors.
Is Qiagen NV's Total Assets too high?
Qiagen NV's current Total Assets is €5,001 Mil. Overall, Qiagen NV has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Total Assets compare to TWST and CRL?
Qiagen NV's Total Assets of €5,001 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Diagnostics & Research company?
A good Total Assets depends on the Medical Diagnostics & Research industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Qiagen NV and its competitors. Qiagen NV's current Total Assets is €5,001 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.89, compared to a current price of €36.41 — trading 20.7% below its estimated fair value. The current Total Assets is €5,001 Mil. Qiagen NV's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current Total Assets is €5,001 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (XTER:QIA) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of €36.41 is trading 20.7% below its estimated GF Value™ of €45.89.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for XTER:QIA:
Total Assets: €5,001 Mil
GF Value™: €45.89 vs. price of €36.41 (20.7% below fair value)
No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
76GF Score
Get the complete analysis for XTER:QIA
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:QIA has been successfully added to your 
